Adding Immunotherapy to Standard Treatment Slows Growth of Advanced Kidney Cancer, with Fewer Side Effects – UroToday
|
Adding Immunotherapy to Standard Treatment Slows Growth of Advanced Kidney Cancer, with Fewer Side Effects
UroToday Published 05 February 2018; Truckee, CA (UroToday.com) In a phase III clinical trial of people with previously untreated metastatic renal cell cancer (mRCC), combining immunotherapy atezolizumab with targeted therapy bevacizumab delayed cancer growth … |
